Endocrine Abstracts

Introduction: Adrenal insufficiency requires life-long glucocorticoid replacement. Conventional therapies fail to mimic endogenous cortisol circadian rhythm. Clock genes are essential components of the molecular machinery controlling organ’s circadian function and are influenced by glucocorticoids. However, clock genes expression has never been investigated in patients with adrenal insufficiency (AI).Aim: To evaluate the effect of the timing of gluc...

HCC is a difficult-to-treat-cancer with poor prognosis. EVOLVE-1 trial demonstrated that EVE did not improve overall survival in molecularly and clinically unselected patients with advanced HCC resistant to sorafenib. In selected patients, the well-established antitumor effect of EVE could make this a potential adjuvant therapy. Unfortunately, EVE acquired resistance due to the tumor adaptation to chronic drug use is a current challenge. VitD was deemed as potential regimen to...

Acromegaly is a disorder characterized by overproduction of growth hormones (GH), which causes tissue growth in the body and comorbidities and symptoms. While prior studies examined comorbidities commonly associated with acromegaly, few have long follow-up periods necessary to characterize the long-term comorbidity profile of patients with acromegaly. There is limited literature on real-world treatment patterns of patients with acromegaly. This study describes the long-term pr...

Acromegaly is a rare disorder characterized by the overproduction of growth hormone (GH) and elevated insulin-like growth factor-1 (IGF1). While some studies have investigated the potential associations between biochemical control (i.e., normalization of IGF-1 and/or GH) and comorbidities/symptoms, few studies have long-term follow-up. This study assessed the association between biochemical control and selected comorbidities/symptoms in patients with acromegaly using real worl...

Long-term biochemical control (i.e., normalization of growth hormone [GH] and insulin-like growth factor-1 [IGF1]) is the goal of treatment of acromegaly. Few studies have characterized the sustainability of GH/IGF1 levels in acromegaly patients. This study aimed to identify long-term time trends of GH, IGF1 levels, and biochemical control in patients with acromegaly using longitudinal real world data. Medical records of adult patients with a confirmed acromegaly diagnosis, &#...

Cushing’s syndrome (CS) is a rare endocrine disease caused by a chronic exposure to endogenous cortisol or exogenous glucocorticoids (GCs). Among multiple comorbidities, impairment of skeletal muscle mass and strength affects 40–70% of patients with active CS and persist even after long-term disease remission. In pathological conditions, GCs excess sustain muscle atrophy and weakness affecting type II muscle fibers. Muscle-specific microRNAs, defined myomiRs, are in...

During 2020 spring, national lockdown was adopted in Italy to prevent COVID-19 pandemic spread. Restrictive measures, including lockdowns, were associated with impaired psychological outcome, mainly increased perceived stress and anxiety, in general population. As transgender people (T*) are associated with higher prevalence of perceived stress, anxiety, and depression, higher psychological vulnerability during lockdowns cannot be excluded. The aim of the PICARD study was the ...

Objectives: To describe the baseline characteristics of individuals enrolled in CAHtalyst (NCT04490915), a randomized, double-blind, placebo-controlled, Phase 3 study evaluating the safety and efficacy of crinecerfont (a corticotropin-releasing factor type 1 receptor [CRF1] antagonist) in adults with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD).Methods: The study included adults (age ≥18 years) with cl...

Background: Glucocorticoids (GC) are potent entrainers of the circadian clock, however their effect on biological rhythms in human chronic exposure have been poorly studied. Endogenous hypercortisolism (Cushing’s Syndrome, CS) is a rare condition, in which circadian disruption is sustained by a tumorous source of GC excess, offering the unique opportunity to investigate the in vivo chronic effects of GC.Methods: In a 12-month prospective mu...

Introduction: Diabetes mellitus (DM) and hypertension are common comorbidities that pose significant clinical burden in Cushing’s syndrome patients and may be improved by normalising cortisol. In two Phase III trials (LINC3 [NCT02180217]; LINC4 [NCT02697734]), osilodrostat, a potent oral 11β-hydroxylase inhibitor, provided reductions in cortisol and improved clinical manifestations of hypercortisolism in most Cushing’s disease (CD) patients. Here, we describe ch...